SHANGHAI and BOSTON, Nov. 18, 2024 /PRNewswire/ -- VelaVigo Cayman Limited (VelaVigo, iCareab's most important partner), a biotechnology firm dedicated to the research and development of multi-specific antibodies and antibody-drug conjugates (ADCs), today disclosed that it has signed a pact with Avenzo Therapeutics, Inc. (Avenzo) which provides Avenzo with an exclusive option for an exclusive license to develop, produce, and market a potentially groundbreaking Nectin4/TROP2 bispecific ADC worldwide (excluding Greater China). VelaVigo will retain rights for Greater China and plans to partner with Avenzo in international development. Click here for more details.